Navigation Links
Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
Date:6/3/2010

f Medicine to earn his medical degree and is board certified in internal medicine and infectious disease.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Anthera Presents Data on Varespladib at ATVB Meeting
5. Anthera Pharmaceuticals Forms Scientific Advisory Board
6. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  In recognition of World Hemophilia Day, Biogen  (NASDAQ: ... illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Superdome and Denver,s Coors Field ... 17, and coincide with hemophilia community events in a dozen ...
(Date:4/16/2015)... ChemRar High Tech ... R&D group, and Lancet, Russian Distribution Company, ... commercialization of new medicines in ... stimulate the innovative development of the Russian ... ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , Through ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Fairleigh ... Joseph V. Gulfo to become the Executive Director ... Simultaneously, FDU announced the kick-off of the Initiative ... spearheaded by Dr. Gulfo, under the Rothman Institute ... of Business) and in collaboration with FDU’s School ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... PARK, N.C., Jan. 14, 2011 Talecris Biotherapeutics Holdings Corp. ... established a new record date and meeting date for the ... merger agreement under which Grifols (GRF.MC) will acquire TLCR. ... on January 11, 2011 will be entitled to vote at ...
... now open for StemCONN 2011. The full-day ... cell research, will take place Tuesday, March 22, in ... the UConn Health Center (commercial session and tour). ... http://stemconn.org/ . StemCONN 2011 will feature a ...
... reversal of tinnitus, a debilitating hearing impairment affecting at ... 40 percent of military veterans, according to an article ... Nature . Researchers Dr. Michael Kilgard and ... Dallas and University-affiliated biotechnology firm MicroTransponder report that stimulation ...
Cached Biology Technology:Nature article focuses on tinnitus treatment 2Nature article focuses on tinnitus treatment 3
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Ecology drives evolution. In today,s issue of the journal ... growing evidence that the reverse is also true, and ... how environmental change affects species and vice-versa. A ... a Galpagos ground finch, Geospiza fortis. In this species, ...
... available in French . , Montreal, January 28, 2011 ... a rare form of cancer that caused a strange combination of ... his stomach and colon. His medical team was stumped and was ... family: the cause of his disease and the risk for future ...
... University of the Negev (BGU) and the PTT Chemical ... research and development collaboration agreement for commercial development of ... for the production of dihomo gamma-linolenic acid (DGLA- Omega ... Parietochloris incise. The joint research will focus on optimizing ...
Cached Biology News:Cold cases gone hot: Montreal researchers solve decades-old medical mysteries using genetics 2Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain 2
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: